中华胰腺病杂志
中華胰腺病雜誌
중화이선병잡지
CHINESE JOURNAL OF PANCREATOLOGY
2012年
1期
49-51
,共3页
欧娅%贾林%邱嘉华%李伟冬%黄耀星%聂玉强
歐婭%賈林%邱嘉華%李偉鼕%黃耀星%聶玉彊
구아%가림%구가화%리위동%황요성%섭옥강
胰腺炎,急性坏死性%肿瘤坏死因子%单克隆抗体%Infliximab%肠道屏障
胰腺炎,急性壞死性%腫瘤壞死因子%單剋隆抗體%Infliximab%腸道屏障
이선염,급성배사성%종류배사인자%단극륭항체%Infliximab%장도병장
Pancreatitis,acute necrotizing%Tumor necrosis factor-alpha%Monoclonod antibodies%Infliximab%Intestinal barrier function
目的 探讨infliximab(TNF-α单抗)对大鼠急性坏死性胰腺炎(ANP)并多器官功能障碍综合征(MODS)模型肠动力及肠屏障损害的保护作用.方法 30只SD大鼠按完全随机法分为假手术组、ANP组和infliximab组.经胰胆管逆行注射4.5％牛磺胆酸钠制备大鼠ANP并MODS模型,infliximab组于建模后6h经尾静脉给予infliximab 8 mg/kg体重,对照组胰胆管逆行注射等量生理盐水.24h后处死大鼠,检测血淀粉酶、TNF-α水平及二胺氧化酶(DAO)、D-乳酸含量；胰腺及小肠组织常规病理检查及评分；碳素墨水法测小肠推进率.结果 对照组、ANP组、infliximab组血清淀粉酶水平分别为(1125±331)、( 11024 ±2203)、(545±30) U/L；TNF-α水平为(12.1±4.0)、(107.6±18.5)、(75.8±5.9) U/L；胰腺病理评分为(2.25±0.38)、(14.1±0.22)、(3.93±0.67)分；小肠病理评分为(2.29±0.32)、(6.61 ±0.58)、(3.91 ±0.41)分；血清DAO含量为(87.88±34.51)、( 146.30±12.99)、(115.00±18.58) μg/L；D-乳酸含量为(1.50±0.49)、(2.32±0.35)、(2.02 ±0.25) mmol/L;小肠推进率为(0.64±0.04)％、(0.28±0.08)％、(0.52 ±0.09)％,各组间比较差异均有统计学意义(P值均＜0.05).结论 早期使用infliximab可有效改善ANP大鼠的胃肠动力功能及减轻肠屏障损害.
目的 探討infliximab(TNF-α單抗)對大鼠急性壞死性胰腺炎(ANP)併多器官功能障礙綜閤徵(MODS)模型腸動力及腸屏障損害的保護作用.方法 30隻SD大鼠按完全隨機法分為假手術組、ANP組和infliximab組.經胰膽管逆行註射4.5％牛磺膽痠鈉製備大鼠ANP併MODS模型,infliximab組于建模後6h經尾靜脈給予infliximab 8 mg/kg體重,對照組胰膽管逆行註射等量生理鹽水.24h後處死大鼠,檢測血澱粉酶、TNF-α水平及二胺氧化酶(DAO)、D-乳痠含量；胰腺及小腸組織常規病理檢查及評分；碳素墨水法測小腸推進率.結果 對照組、ANP組、infliximab組血清澱粉酶水平分彆為(1125±331)、( 11024 ±2203)、(545±30) U/L；TNF-α水平為(12.1±4.0)、(107.6±18.5)、(75.8±5.9) U/L；胰腺病理評分為(2.25±0.38)、(14.1±0.22)、(3.93±0.67)分；小腸病理評分為(2.29±0.32)、(6.61 ±0.58)、(3.91 ±0.41)分；血清DAO含量為(87.88±34.51)、( 146.30±12.99)、(115.00±18.58) μg/L；D-乳痠含量為(1.50±0.49)、(2.32±0.35)、(2.02 ±0.25) mmol/L;小腸推進率為(0.64±0.04)％、(0.28±0.08)％、(0.52 ±0.09)％,各組間比較差異均有統計學意義(P值均＜0.05).結論 早期使用infliximab可有效改善ANP大鼠的胃腸動力功能及減輕腸屏障損害.
목적 탐토infliximab(TNF-α단항)대대서급성배사성이선염(ANP)병다기관공능장애종합정(MODS)모형장동력급장병장손해적보호작용.방법 30지SD대서안완전수궤법분위가수술조、ANP조화infliximab조.경이담관역행주사4.5％우광담산납제비대서ANP병MODS모형,infliximab조우건모후6h경미정맥급여infliximab 8 mg/kg체중,대조조이담관역행주사등량생리염수.24h후처사대서,검측혈정분매、TNF-α수평급이알양화매(DAO)、D-유산함량；이선급소장조직상규병리검사급평분；탄소묵수법측소장추진솔.결과 대조조、ANP조、infliximab조혈청정분매수평분별위(1125±331)、( 11024 ±2203)、(545±30) U/L；TNF-α수평위(12.1±4.0)、(107.6±18.5)、(75.8±5.9) U/L；이선병리평분위(2.25±0.38)、(14.1±0.22)、(3.93±0.67)분；소장병리평분위(2.29±0.32)、(6.61 ±0.58)、(3.91 ±0.41)분；혈청DAO함량위(87.88±34.51)、( 146.30±12.99)、(115.00±18.58) μg/L；D-유산함량위(1.50±0.49)、(2.32±0.35)、(2.02 ±0.25) mmol/L;소장추진솔위(0.64±0.04)％、(0.28±0.08)％、(0.52 ±0.09)％,각조간비교차이균유통계학의의(P치균＜0.05).결론 조기사용infliximab가유효개선ANP대서적위장동력공능급감경장병장손해.
Objective To evaluate the effects of infliximab (TNF-α monoclonal antibody ) on intestinal barrier injury in ANP complicated with MODS in a rat model.Methods Thirty SD rats were randomly divided into sham operation group (SO),ANP group and infliximab treatment group.Sodium taurocholate (4.5％) was injected into the pancreatic duct to induce ANP complicated with MODS model.Infliximab (8 mg/kg) was injected via tail vein in 6h after modeling in infliximab group.Same amount of 0.9％ NS was injected into the pancreatic duct in SO group.After 24 h of modeling,all rats were sacrificed,intestine and pancreas samples were collected for pathologic examination.The blood samples were harvested.The serum levels of amylase,TNF-α,diamine oxidase( DAO),D-lactate,and the rate of carbon propelling in ileum were measured.Results The serum levels of amylase were ( 1125 ± 331 ),( 11024 ± 2203 ),( 545 ±30) U/L in SO group,ANP group and infliximab group; the serum levels of TNF-α were (12.1 ± 4.0),(107.6 ± 18.5),(75.8 ±5.9) U/L; the pathological scores of pancreas were 2.25 ±0.38,14.10 ±0.22,3.93 ± 0.67,the difference among the 3 groups was statistically significant ( P ＜ 0.05 ).The pathological scores of intestine were 2.29 ± 0.32,6.61 ± 0.58,3.91 ± 0.41 ; the DAO levels were ( 87.88 ± 34.51 ),(146.30 ±12.99),(115.00 ± 18.58) ng/ml; the D-lactate levels were (1.50 ±0.49),(2.32 ± 0.35),(2.02 ± 0.25 )mmol/L; and the rates of carbon propelling in ileum were (0.64 ± 0.04 )％,(0.28 ±0.08)％,(0.52 ±0.09)％,the difference among the 3 groups was statistically significant (P ＜0.05).Conclusions Infliximab can effectively prevent dysfunction of intestinal barrier and improve motility in ANP rats.
